Atara Biotherapeutics, Inc. stock is down -52.48% since 30 days ago. The next earnings date is Feb 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 November’s closed higher than October. In the last 2 Unusual Options Trades, there were 2 PUTs. 0% of analysts rate it a buy.
Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.